1. Home
  2. CRNX

as 06-20-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 2.8B IPO Year: 2018
Target Price: $75.00 AVG Volume (30 days): 676.7K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.82 EPS Growth: N/A
52 Week Low/High: $24.10 - $62.53 Next Earning Date: 08-07-2025
Revenue: $760,000 Revenue Growth: -61.50%
Revenue Growth (this year): 402.12% Revenue Growth (next year): 770.88%

CRNX Daily Stock ML Predictions

Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Betz Stephen F. CRNX Chief Scientific Officer Jun 12 '25 Sell $32.23 97,483 $3,141,877.09 99,713

Share on Social Networks: